Rybodyn
RyboDyn is a biotechnology company pioneering immunotherapy development by unlocking the dark proteome using its proprietary RyboCypher™ platform. This platform combines novel RNA sequencing with AI models to reveal hidden proteins encoded by non-coding regions of the genome, transforming these discoveries into a pipeline of antibody-based drug candidates targeting disease-specific antigens. RyboDyn collaborates with leading institutions like Moffitt Cancer Center and Eli Lilly to validate and accelerate its first-in-class immunotherapies, aiming to deliver breakthrough treatments for cancer and other diseases by targeting previously undetectable biological signals.
Rybodyn
RyboDyn is a biotechnology company pioneering immunotherapy development by unlocking the dark proteome using its proprietary RyboCypher™ platform. This platform combines novel RNA sequencing with AI models to reveal hidden proteins encoded by non-coding regions of the genome, transforming these discoveries into a pipeline of antibody-based drug candidates targeting disease-specific antigens. RyboDyn collaborates with leading institutions like Moffitt Cancer Center and Eli Lilly to validate and accelerate its first-in-class immunotherapies, aiming to deliver breakthrough treatments for cancer and other diseases by targeting previously undetectable biological signals.